Personalized cancer vaccine cuts melanoma recurrence risk by 42%

An international trial involving 1,137 patients showed that a personalized vaccine reduced the risk of recurrence or death by 42% in high-risk melanoma cases. This marks the first time this therapeutic approach has demonstrated a clear clinical benefit for patients.